Herpes Zoster Market Overview

The herpes zoster market is anticipated to reach USD 224 Million by 2030 at 8.90% CAGR during the forecast period 2022-2030

 Currently, there are only two vaccines licensed and available in the US for shingles namely Zostavax (zoster vaccine live) and Shingrix (recombinant zoster vaccine). Both these vaccines are safe and effective and has potential side effects.Generally, the diagnosis of this condition is through laboratory testing. Additionally, the first line of treatment is through medication which include oral medicines (Antihistamines), topical (numbing creams, gels, or patches), and vaccines. Typically, the vaccines are administered to the geriatric population as they are at a higher risk to contract this disease.The Herpes Zoster Market Analysis is expected to witness tremendous growth owing to rising incidence of herpes zoster coupled with rising geriatric population are factors contributing towards the growth of the market. Moreover, the risk of developing herpes zoster increases with age. However, challenges such as the limited number of pipeline agents for the treatment of herpes zoster despite the growing incidence of the infection worldwide is likely to curb the market growth during the forecast period.

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/7137

Competitive Landscape:

Companies are intensely competitive when it comes to take charge of the global herpes zoster market. MRFR included several of them in their report on the market to profile them and understand latest trends. These companies are Foamix Pharmaceuticals (Israel), Astellas Pharma Inc. (Japan), GlaxoSmithKline plc (UK), Geneone Life Science (South Korea), NAL Pharma (Hong Kong), Merck & Co. Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Novartis AG (Switzerland), TSRL, Inc. (US) and others.

In June 2019, an article published in 2minute medicine revealed that kids who were given varicella vaccine are less likely to show signs of herpes zoster.  The research was conducted on people under 18 years of age. The varicella zoster vaccine is a live attenuated vaccine that can be linked with reactivation of the latent herpes zoster.

In a different study, conducted in May 2019, it is revealed that Sky Zoster NBP608 herpes zoster vaccine is at per with Mercks Zostavax. This could solve South Korea problem regarding the launch of Shingrix. 

 Segmentation

The global herpes zoster market is segmented into Diagnosis, application, end-users. The herpes zoster market, by Diagnosis, the market is segmented into laboratory testing and others. The laboratory testing segment is further categorized into immunofluorescent microscopy, real-time Polymerase Chain Reaction (PCR), serological testing. The treatment and prevention segment for the global herpes zoster market is divided into antiviral medications, narcotic medications, anti-inflammatory medications, antihistamines, anticonvulsants, capsaicin, numbing creams, gels, or patches, vaccines, and others. The route of administration segment for the global herpes zoster market is divided into oral, topical, and others. The end-user segment for the global herpes zoster market is divided into hospitals & clinics, diagnostic centers, research & academic institutes, home care settings, and others.

Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/herpes-zoster-market-7137  

 Regional Analysis:

The Americas is the largest in the market owing to the increasing government support for vaccination and the highly advanced healthcare facilities to address the growing incidence of the infection. For instance, as per the Population Reference Bureau (2018), the number of Americans aged 65 or above are projected to be doubled from 46 million (2016) to 98 million by 2060, with the subsequent rise in the older age group to nearly 24 percent of the total population from the present 15 percent. The disease is prevalent in older adults usually between 60 -80 years due to the weak immune system thereby providing an opportunity for future growth of the market.

European region is the second largest market over the forecast period due to factors such as the emerging innovative vaccines for disease management and rising incidence of herpes zoster will provide considerable growth opportunities to herpes zoster treatment companies in the European region. The growing prevalence of the herpes zoster infection in the regions such as Asia Pacific and Middle East & Africa which will emerge as the fastest growing regions in the global herpes zoster infection treatment market.

Table Of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

 About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com